Showing 1901-1910 of 2314 results for "".
- Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congresshttps://modernod.com/news/nicox-announces-presentations-of-additional-ncx-470-data-at-the-upcoming-world-glaucoma-congress/2481481/Nicox SA announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC), which will be held from June 28 to July 1, 2023 in Rome, Italy. Details of the presentations: Poster Title: Effects of NCX 470, a Nitric Oxide (NO)-Donati
- LumiThera Announces Sustained Vision Improvement for 24 Months in Dry AMD Subjects from US LIGHTSITE III Trialhttps://modernod.com/news/lumithera-announces-sustained-vision-improvement-for-24-months-in-dry-amd-subjects-from-us-lightsite-iii-clinical-trial-data/2481469/LumiThera announced 24-month data from its LIGHTSITE III multicenter clinical trial which demonstrated sustained vision improvement in dry age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked
- Cedars-Sinai Analysis Evaluates How Retinal Changes Correspond to Cognitive Changes in Alzheimer’s Diseasehttps://modernod.com/news/new-insights-eye-damage-in-alzheimers-disease-patients/2481455/Cedars-Sinai investigators have produced an analysis evaluating how retinal changes correspond to brain and cognitive changes in Alzheimer’s disease patients. Investigators looked at retinal and brain tissue samples collected over 14 years from 86 human donors—the
- Akorn Files for Chapter 7 Bankruptcy; to Close All US Siteshttps://modernod.com/news/akorn-pharma-to-close-all-us-sites/2481445/Akorn Pharmaceuticals, a maker of generic and branded drugs, announced it is ceasing operations. The company, which offered more than 20 ophthalmic products, has filed for chapter 7 bankruptcy and is shutting down US operations. The news was first
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels From Childhood Vaccineshttps://modernod.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/Horizon Therapeutics announced new data suggest Uplinza does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. Uplinza is the first and only B-cell-depleting monotherapy approved by the FDA and the European Commission for the tre
- Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Studyhttps://modernod.com/news/skye-bioscience-receives-positive-safety-review-of-sbi-100-ophthalmic-emulsion-after-second-cohort-of-phase-1-study/2481432/Skye Bioscience has received a positive recommendation following a prespecified data review by the safety review committee based on dosing of the second cohort of eight healthy participants of its phase 1 study of SBI-100 ophthalmic emulsion. The SRC has recommended that the trial conti
- FDA Accepts Orasis Pharmaceuticals' NDA for CSF-1 for the Treatment of Presbyopiahttps://modernod.com/news/fda-accepts-orasis-pharmaceuticals-nda-for-csf-1-for-the-treatment-of-presbyopia/2481424/Orasis Pharmaceuticals announced that the FDA has accepted for review its new drug application (NDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 22, 2023. "We
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- VSP Vision Names New President of VSP Ventureshttps://modernod.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/VSP Vision announced that Kathleen Steele has been named president of VSP Ventures. In the role, Ms. Steele will lead the company’s business unit that provides care-focused choices for doctors of optometry looking for practice transition options. She will report to Kate Renwick-Es
- Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/Ocuphire Pharma announced the initiation of the VEGA-2 phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine (LDP) therapy for presbyopia.